FDA Adverse Event Malfunction Summary report: N

COAGUCHEK ® XS SYSTEM

MDR report key: 5580598 · Received April 15, 2016

Report

Report Number
1823260-2016-00439
Event Type
Malfunction
Date Received
April 15, 2016
Date of Event
March 14, 2016
Report Date
June 2, 2016
Manufacturer
ROCHE DIAGNOSTICS
Product Code
GJS
PMA / PMN Number
K062925
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
PATIENT FAMILY MEMBER OR FRIEND

Narratives

Additional Manufacturer Narrative · 1

THE CUSTOMER RETURNED THE SUSPECT STRIPS AND THE METER. THE RETURNED METER AND STRIPS WERE TESTED IN COMPARISON TO A RETENTION METER AND MASTERLOT STRIPS. ALL OF THE INR VALUES WERE WITHIN THE SPECIFIED MAXIMUM DIFFERENCE BETWEEN MEASUREMENTS. THERE WERE NO ERROR MESSAGES THAT OCCURRED. THE COMPLAINT HAS NOT BEEN SUBSTANTIATED.

Description of Event or Problem · 1

IT WAS STATED THAT WHILE TESTING ON (B)(6) 2016 THE CUSTOMER OBTAINED A RESULT OF 5.2 INR ON HER COAGUCHEK XS METER (SERIAL NUMBER (B)(4)) WHILE A LABORATORY RESULT DONE WITHIN 7 HOURS FROM HER METER RESULT WAS 3.4 INR. IT WAS REPORTED THAT THE LABORATORY USES THE DADE INNOVIN REAGENT. THE CUSTOMER STATED THAT THERE WAS NO MEDICATION CHANGE OR TREATMENT RECEIVED DUE TO THE READINGS. THE CUSTOMER DOES NOT HAVE POLYCYTHEMIA. SHE DOES NOT HAVE ANY ANTIPHOSPHOLIPID ANTIBODIES. SHE IS NOT ON ANY DIRECT THROMBIN INHIBITORS. THERE WAS NO CHANGES IN HER DIET OR MEDICATION. THE CUSTOMER'S THERAPEUTIC RANGE IS 2.0-3.0 INR. THERE WAS NO ADVERSE EVENT. THE SUSPECT PRODUCT WAS REQUESTED TO BE RETURNED AND THE REPLACEMENT PRODUCT WAS SENT. THE RELEVANT RETENTION TEST STRIPS (LOT 200782-21) WERE TESTED IN COMPARISON WITH THE CURRENT MASTER LOT COAGUCHEK XS PT TEST STRIP (LOT 230734-80). THERE WERE NO ERROR MESSAGES THAT OCCURRED. THE RETENTION SAMPLES WERE ACCEPTABLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
236008 COAGUCHEK ® XS SYSTEM PROTHROMBIN TIME TEST STRIPS GJS ROCHE DIAGNOSTICS NA 20078221

Patients

Seq Age Sex Outcome Treatment
1 66 YR